Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1018 participants
OBSERVATIONAL
2006-04-01
2006-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pramipexole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* are able to provide written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
* have idiopathic Parkinsons disease according to the United Kingdom Parkinsons Disease Society Brain Bank Diagnostic Criteria for Parkinsons disease
* show no impairment of cognitive function (MMSE score ?24)
* are with or without symptoms of depression (full range)
* are stable on anti-Parkinson/anti-depressive treatment for at least 1 month before entering the study
* are or are not on concomitant antidepressant treatment
* are in the on state during the observation period
* did not previously undergo PD surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
Boehringer Ingelheim BV/Alkmaar
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site
Innsbruck, , Austria
Boehringer Ingelheim Investigational Site
Vienna, , Austria
Boehringer Ingelheim Investigational Site
Vienna, , Austria
Hopital Rangueil
Toulouse, , France
Hopital Purpan
Toulouse, , France
Neurologisches Fachkrankenhaus fur
Beelitz-Heilstätten, , Germany
Universitatsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Boehringer Ingelheim Investigational Site
Gera, , Germany
Gertrudis-Kliniken Biskirchen
Leun, , Germany
Boehringer Ingelheim Investigational Site
Unterhaching, , Germany
Parkinson Klinik Wolfach
Wolfach, , Germany
Policlinico di Catania
Catania, , Italy
Azienda Ospedaliera S. Martino
Genova, , Italy
Universita Federico II
Napoli, , Italy
Universita La Sapienza di Roma
Roma, , Italy
Academisch Ziekenhuis Maastricht
Maastricht, , Netherlands
Hospital de Cruces. Neurology
Baracaldo / Bilbao, , Spain
Hospital Clinic i Provincial. Neurology
Barcelona, , Spain
Hospital Puerta del Mar. Neurology
Cadiz, , Spain
Clinica Hildebrand
Brissago, , Switzerland
Hopital Cantonal (HUG)
Geneva, , Switzerland
Kantonsspital St. Gallen
Sankt Gallen, , Switzerland
Boehringer Ingelheim Investigational Site
London, , United Kingdom
Boehringer Ingelheim Investigational Site
Newark, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
248.597
Identifier Type: -
Identifier Source: org_study_id